Anti-CD46 antibodies and methods of use
US11434301B2 · kind B2 · utility
3Cited by
2References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 2017 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | Jun 16, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods of treating a subject having a cancer characterized by a modification at biomarker 1q21, which comprises administering to the subject a therapeutically effective amount of an anti-CD46 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.